SARP 3

SARP 3
(A research study for pediatric patients who have been diagnosed with Asthma, ages 6-18)


SARP- Severe Asthma Research Program

This study is will compare participants with severe asthma to those with milder forms of asthma over a period of 3 years. The study will follow the overall health as well as the health of the lungs through various blood tests, breathing tests and questionnaires.

At the end of Visit 2, participants will receive a one-time injection of Triamcinalone acetonide. This is an FDA-approved steroid medication for the treatment of inflammation in people with asthma. The purpose for this treatment is to allow the researchers to compare different measures of inflammation before and after the steroid treatment to see if there are any changes. Participants will continue their usual asthma medications throughout the duration of this study.

Eligible participants will receive free breathing tests, allergy testing, other study tests, physical exams, and monetary compensation for each completed study visit.

If you or someone you know is interested in learning more about the SARP 3 study, please contact Denise Whitlock 404-712-1773 or drwhitl@emory.edu.